Makriyannis will assist in guiding ICC funded Biotii with their corporate mandate of securing a robust portfolio of d efendable IP. Traditional cultivation of cannabis plants for the purpose of extracting cannabidiolic acid ( “ CBDA ” ), THC and CBD is a time, labour and resource intensive endeavour that can result in depressed extraction yields of approximately 2.5 per cent.Īrmed with a successful track record of generating cannabinoid centric intellectual property (“IP”), including the authoring of 37 related patents with in the United States, Dr. The lowest production costs in the space.īiotii's scalable synthesizing process will enable the manufactur ing of enigmatic cannabis compounds, as well as THC and CBD at materially lower costs when compared with conventional cultivation and extraction processes. Highly specialized knowledge of cannabinoid biochemistry, as well as the macro human endocannabinoid system equips ICC and Biotii with a first mover competitive advantage to economically scale its synthesized cannabinoid platform.īy 2020, ICC and Biotii intends to establish processes to efficiently mass-produce CBD/THC in quantities of hundreds of metric tonnes per annum, which boast: Makriyannis will champion Company’s pursuit of biosynthesizing cannabinoids ide ntical to those found in nature, with the objective of standardizing pharmacological effects within t he human endocannabinoid system. Makriyannis is credited with numerous scientific cannabinoid-centric achievements, including the discovery of cannabinoid receptor antagonists, as well as pioneering inmetabolically stable endocannabinoids. A professor of Chemistry and Chemical Biology in the Department of Medicinal Chemistry at Northeastern University, Dr. (“ Biotii ”) has entered into a cannabinoid pharmaceutical advisory agreement (the “Agreement”) with Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. U )(FWB: 8K51)(OTC: WLDCF ) ( the “Company” or " ICC " or “ International Cannabis ” ) is pleased to announce that the Company, alongside Biotii Technologies Corp.
VANCOUVER, British Columbia, July 23, 2019 - ICC International Cannabis Corp.
0 kommentar(er)
